By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...
CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...
By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...
The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.
Investing News Network on MSN
Moderna to pay US$950 million to settle COVID-19 vaccine patent dispute
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...
The updated 2024-2025 mRNA COVID vaccine from Moderna does not appear to carry the same risk for myocarditis in young adults that the first mRNA COVID vaccines did, suggested research presented at the ...
About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...
The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...
Moderna has filed with the Food and Drug Administration for emergency use authorization for its COVID-19 vaccine for people ages 12 to 17, according to a news release from the company. Moderna's COVID ...
Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 shot mNEXSPIKE infringes a patent related to COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results